In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opsona Therapeutics Ltd.

www.opsona.com

Latest From Opsona Therapeutics Ltd.

Alexion’s Soliris Slips Up In Pivotal PROTECT Kidney Transplant Study

A difficult December for Alexion sees a pivotal study of its blockbuster Soliris failing to show any benefit in preventing delayed graft function in kidney transplant patients, an indication for which there are no approved treatments.

Research & Development Clinical Trials

Germany’s Immatics Biotech Raises $46M In Series D To Complete Cancer Vaccine Development

With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.

BioPharmaceutical Germany

Recent Financings Of Private Companies, June 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device

Irish Biotech Opsona Adds Two New Corporate VCs In $43M Series C

Irish biotech Opsona Therapeutics recently raised $43 million with the help of four corporate VCs, for use in developing its potential first-in-class product for preventing delayed graft function in high-risk renal transplant patients.

BioPharmaceutical Ireland
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Opsona Therapeutics Ltd.
  • Senior Management
  • Martin Welschof, PhD, CEO
    Luke O'Neill, PhD, CSO
    Mary Reilly, VP, Pharmaceutical Dev. & Ops.
    Conor Dalton, Dir., Finance
  • Contact Info
  • Opsona Therapeutics Ltd.
    Phone: (353) 1 6770223
    Second Floor, Ashford House
    Tara Street
    Dublin 2,
    Ireland
UsernamePublicRestriction

Register